Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca ... slides and supplementary data are ...

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Cantor Fitzgerald raised the firm’s price target on Gilead (GILD) to $80 from $70 and keeps a Neutral rating on the shares post the Q3 ...

Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

Gilead Sciences, Inc. (NASDAQ:GILD ... The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...